The social media pressure campaign was just a part of the pharmaceutical industry’s successful lobbying blitz to retain patents — and make record profits.

by Lee Fang, The Intercept

In mid-December 2020, Nina Morschhaeuser, a lobbyist for Twitter in Europe, emailed colleagues with a dire warning. The drugmaker BioNTech, along with the German government, had contacted her with news of an imminent “campaign targeting the pharmaceutical companies developing the COVID-19 vaccine,” she wrote.

“The authorities are warning about ‘serious consequences’ of the action, i.e. posts and a flood of comments ‘that may violate TOS’ as well as the ‘takeover of user accounts’ are to be expected,” wrote Morschhaeuser. “Especially the personal accounts of the management of the vaccine manufacturers are said to be targeted. Accordingly, fake accounts could also be set up.”

Activists stage rally and die-in under the banner Free the Vaccine demanding for free distribution of COVID-19 vaccine to poor countries in Midtown Manhattan

The campaign they were concerned about was the launch of an international push to force the drug industry to share the intellectual property and patents associated with coronavirus vaccine development. Making the patents available, in turn, would allow countries across the world to swiftly manufacture generic vaccines and other low-cost therapeutics to deal with the ongoing pandemic.

Morschhaeuser, while alerting several site integrity and safety teams at Twitter, forwarded on an email from BioNTech spokesperson Jasmina Alatovic, who asked Twitter to “hide” activist tweets targeting her company’s account over a period of two days.

Read More